HER2-positive BCs constitute about 14% of all female BC cases, with 18.8 new diagnoses per 100,000 women; among these, the majority are HR-positive (HR-positive = 13.3 versus HR-negative = 5.5), and the 5-years survival is better than that of patients with HR-negative/HER2-positive BC in all settings of the disease [2]. Here, ERBB2 is linked to breast cancer.